| Name | Recombinant Human BMPG (C-6His) |
| Purity | Greater than 95% as determined by reducing SDS-PAGE |
| Endotoxin level | <1 EU/µg as determined by LAL test. |
| Construction | Recombinant Human Bone Marrow Proteoglycan is produced by our Mammalian expression system and the target gene encoding Leu17-Tyr222 is expressed with a 6His tag at the C-terminus. |
| Accession # | AAH05929.1 |
| Host | Human Cells |
| Species | Human |
| Predicted Molecular Mass | 24.6 KDa |
| Buffer | Supplied as a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
| Form | Liquid |
| Shipping | The product is shipped on dry ice/polar packs.Upon receipt, store it immediately at the temperature listed below. |
| Stability&Storage | Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles. |
Alternative Names
Bone Marrow Proteoglycan; BMPG; Proteoglycan 2; Eosinophil Granule Major Basic Protein; EMBP; MBP; Pregnancy-Associated Major Basic Protein; PRG2; MBP
Background
Bone Marrow Proteoglycan (BMPG) is a secreted protein that contains one C-type lectin domain. BMPG is the predominant constituent of the crystalline core of the eosinophil granule. BMPG is highly expressed in placenta and pregnancy serum. BMPG may be involved in antiparasitic defense mechanisms as a cytotoxin and helminthotoxin. BMPG induces non-cytolytic histamine release from human basophils. In addition, BMPG also participated in antiparasitic defense mechanisms and immune hypersensitivity reactions.
Note
For Research Use Only , Not for Diagnostic Use.